Journal of Medicinal Chemistry · 2002 · 41 citations · 7 references
Life SciencesMedicinal ChemistryPharmacologyDrug DiscoveryLipid BiochemistrySynthetic Medicinal ChemistryCholesterol MetabolismLipid ChemistryLipid MetabolismLipid PeroxidationLipid-lowering TherapyLipoprotein MetabolismAntioxidant PropertiesLdl Cholesterol LoweringLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol ReductionLow-density Lipoprotein ParticlesMorpholine ChemistryNitric OxidePlasma Cholesterol Levels
The synthesis and evaluation of activity of some nitric acid esters of substituted morpholines are presented. All compounds inhibit lipid peroxidation and reduce cholesterol (20-63%) and triglyceride (37-85%) plasma levels. The more potent NO donors 14 and 17 specifically reduce low-density lipoprotein (LDL). These data indicate that proper structural modifications to the hypolipidemic and antioxidant morpholines enabling NO production, besides preserving or enhancing the above activities, offer a remarkable reduction of LDL, considered advantageous for antiatheromatic agents.
7
Inhibition of low‐density lipoprotein oxidation by nitric oxide Potential role in atherogenesis
Neil Hogg, B. Kalyanaraman, Joy Joseph et al. · FEBS Letters · 1993 · 405 citations · Full text
Daigo Sumi, Toshio Hayashi, Navin Kumar Thakur et al. · Atherosclerosis · 2001 · 98 citations
Medicine, Cardiology, Pharmacology +15
Francesca Benedini, Giorgio Bertolini, Roberta Cereda et al. · Journal of Medicinal Chemistry · 1995 · 90 citations
Medicine, Cardiology, Pharmacology +17